160 related articles for article (PubMed ID: 29959152)
1. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Flasinski M; Scheibke K; Zimmermann M; Creutzig U; Reinhardt K; Verwer F; de Haas V; van der Velden VHJ; von Neuhoff C; Zwaan CM; Reinhardt D; Klusmann JH
Blood Adv; 2018 Jul; 2(13):1532-1540. PubMed ID: 29959152
[TBL] [Abstract][Full Text] [Related]
2. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome for Down syndrome patients with hematopoietic disorders.
Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS).
Al-Kershi S; Golnik R; Flasinski M; Waack K; Rasche M; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
Klin Padiatr; 2021 Nov; 233(6):267-277. PubMed ID: 34407551
[TBL] [Abstract][Full Text] [Related]
5. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Gamis AS; Alonzo TA; Gerbing RB; Hilden JM; Sorrell AD; Sharma M; Loew TW; Arceci RJ; Barnard D; Doyle J; Massey G; Perentesis J; Ravindranath Y; Taub J; Smith FO
Blood; 2011 Dec; 118(26):6752-9; quiz 6996. PubMed ID: 21849481
[TBL] [Abstract][Full Text] [Related]
6. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
7. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
[TBL] [Abstract][Full Text] [Related]
8. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Hitzler J; Alonzo T; Gerbing R; Beckman A; Hirsch B; Raimondi S; Chisholm K; Viola S; Brodersen L; Loken M; Tong S; Druley T; O'Brien M; Hijiya N; Heerema-McKenney A; Wang YC; Schore R; Taub J; Gamis A; Kolb EA; Berman JN
Blood; 2021 Dec; 138(23):2337-2346. PubMed ID: 34320162
[TBL] [Abstract][Full Text] [Related]
9. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.
Apollonsky N; Shende A; Ouansafi I; Brody J; Atlas M; Aygun B
J Pediatr Hematol Oncol; 2008 Nov; 30(11):860-4. PubMed ID: 18989165
[TBL] [Abstract][Full Text] [Related]
10. Neonatal vesiculopustular eruption in Down syndrome and transient myeloproliferative disorder: A case report and review of the literature.
Brazzelli V; Segal A; Bernacca C; Tchich A; Bolcato V; Croci G; Mina T; Zecca M; Zanette S; Stronati M
Pediatr Dermatol; 2019 Sep; 36(5):702-706. PubMed ID: 31355466
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland.
Dowling GP; Piccin A; Gavin KT; Betts DR; Malone A; Cotter M; Sills A; Evans P; O' Marcaigh A; Smith OP
Ir J Med Sci; 2020 Aug; 189(3):979-984. PubMed ID: 32006388
[TBL] [Abstract][Full Text] [Related]
13. A neonate with a vesiculopustular rash.
Ansari DO; Lapping-Carr G; Alikhan M; Tsoukas ML; Stein SL; de Jong JL
Pediatr Ann; 2015 Jan; 44(1):e1-5. PubMed ID: 25621627
[TBL] [Abstract][Full Text] [Related]
14. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
Chisholm KM; Rivetta CV; Heerema-McKenney A
Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
[TBL] [Abstract][Full Text] [Related]
15. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
16. [Abnormal hematopoiesis in Down syndrome].
Ito E
Rinsho Ketsueki; 2014 Oct; 55(10):1738-47. PubMed ID: 25297735
[No Abstract] [Full Text] [Related]
17. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
18. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
19. Transient myeloproliferative disorder in neonates without Down syndrome: case report and review.
Schifferli A; Hitzler J; Bartholdi D; Heinimann K; Hoeller S; Diesch T; Kühne T
Eur J Haematol; 2015 May; 94(5):456-62. PubMed ID: 24853125
[TBL] [Abstract][Full Text] [Related]
20. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
